WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 1009494% more annual revenue ($20.63B vs $2.04M). GEHC leads profitability with a 10.1% profit margin vs -1.6%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

AIDX

Avoid

18

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.8%8/10

15.8% revenue growth

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

AIDX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.59M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Price/BookValuation
164.0x2/10

Trading at 164.0x book value

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

AIDX profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

AIDX is growing revenue faster at 15.8% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?